Condition (MeSH)
Aberrant Crypt Foci
ClinicalTrials.gov lists 1 trial for Aberrant Crypt Foci or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
5 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Aberrant Crypt Foci itself; the rest are tagged with a narrower condition beneath it.
When did Aberrant Crypt Foci trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2004 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Aberrant Crypt Foci trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Not applicable | 1 |
How many Aberrant Crypt Foci trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Aberrant Crypt Foci? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial. | Cancer prevention research (Philadelphia, Pa.) | 2022 | Yes |
| Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. | PloS one | 2018 | Yes |
| Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. | The Lancet. Oncology | 2012 | Yes |
| Effects of adlay bran and its ethanolic extract and residue on preneoplastic lesions of the colon in rats. | Journal of the science of food and agriculture | 2011 | Yes |
| Dietary Polyacetylenic Oxylipins Falcarinol and Falcarindiol Prevent Inflammation and Colorectal Neoplastic Transformation: A Mechanistic and Dose-Response Study in A Rat Model. | Nutrients | 2019 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.